The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 9, 2022. Its latest SEC filing is a SC 13G/A from Feb 14, 2023.
10-Q for Q3 FY2022, filed Nov 9, 2022
The sections below describe the company as of the FY2021 annual report.
Develops small-molecule drug candidates for patients with blood cancers and bone marrow diseases, including bomedemstat for myelofibrosis, essential thrombocythemia and polycythemia vera.
10-K for FY2021, filed Mar 24, 2022
No revenue was reported.
10-K for FY2021, filed Mar 24, 2022
10-Q for Q3 FY2022, filed Nov 9, 2022
−$16.8MView ↗
8-K, filed Jan 11, 2023
On January 11, 2023, Imago (i) notified the Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that…View ↗
8-K, filed Nov 21, 2022
On November 19, 2022, Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Merck” or “Parent”), M-Inspire Merger Sub, Inc., a…View ↗
Competes with Incyte, Novartis, Bristol-Myers Squibb, CTI BioPharma, AbbVie, Acceleron, Fibrogen, Geron, Kartos, Protagonist, MorphoSys, Roche, 4SC, Epizyme, GlaxoSmithKline, Merck, Oryzon, Salarius, Spectrum, and Taiho
10-K for FY2021, filed Mar 24, 2022For the treatment of MF, Incyte markets ruxolitinib in the United States, and Novartis markets the drug in the rest of the world.…View ↗
Loading...
